AACR's blockbuster INSIGHT study: Combination therapy of tepotinib and gefitinib significantly improves progression-free survival and overall survival in patients with EGFR mutation-positive NSCLC with MET amplification

In the primary analysis of the INSIGHT trial (NCT01982955; median follow-up: 21.

In the primary analysis of the INSIGHT trial (NCT01982955; median follow-up: 21.

At the recent AACR2022 meeting, experts from the University of Malaya School of Medicine and other institutions jointly reported the final analysis results of the INSIGHT trial

Patients with EGFR-mutant (T790M-negative) NSCLC and anti-EGFR resistance, MET gene copy number (GCN) ≥ 5 by FISH and/or MET:CEP7 ≥ 2 and/or MET IHC 2+/3+, were randomized to receive terpoor Titinib 500 mg (450 mg active molecule) + Gefitinib 250 mg QD or CTX

Patients with EGFR-mutant (T790M-negative) NSCLC and anti-EGFR resistance, MET gene copy number (GCN) ≥ 5 by FISH and/or MET:CEP7 ≥ 2 and/or MET IHC 2+/3+, were randomized to receive terpoor Titinib 500 mg (450 mg active molecule) + Gefitinib 250 mg QD or CTX

RESULTS: Among 19 of 55 randomized patients (34.

Efficacy and safety in patients with MET amplification

Overall, compared with CTX, tepotinib plus gefitinib improved PFS (HR=0.

Overall, compared with CTX, tepotinib plus gefitinib improved PFS (HR=0.

In conclusion, in patients with EGFR-mutant NSCLC with MET amplification, tepotinib plus gefitinib significantly improved PFS and OS

source:

source:

https://#!/10517/presentation/20277

https://#!/10517/presentation/20277 https://#!/10517/presentation/20277

Leave a comment here